Janney Montgomery Scott LLC reduced its position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 9.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 68,332 shares of the financial services provider’s stock after selling 7,151 shares during the period. Janney Montgomery Scott LLC owned 0.13% of iShares Biotechnology ETF worth $9,949,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the business. Main Management ETF Advisors LLC lifted its position in shares of iShares Biotechnology ETF by 2.6% in the 2nd quarter. Main Management ETF Advisors LLC now owns 578,835 shares of the financial services provider’s stock worth $79,451,000 after purchasing an additional 14,535 shares during the period. Raymond James Financial Services Advisors Inc. lifted its holdings in iShares Biotechnology ETF by 24.6% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock worth $29,792,000 after buying an additional 42,822 shares during the period. Raymond James & Associates boosted its position in iShares Biotechnology ETF by 4.4% during the 2nd quarter. Raymond James & Associates now owns 189,766 shares of the financial services provider’s stock valued at $26,047,000 after acquiring an additional 7,931 shares in the last quarter. Osaic Holdings Inc. grew its holdings in shares of iShares Biotechnology ETF by 9.4% during the 1st quarter. Osaic Holdings Inc. now owns 160,173 shares of the financial services provider’s stock worth $21,985,000 after acquiring an additional 13,777 shares during the period. Finally, Albion Financial Group UT raised its position in shares of iShares Biotechnology ETF by 0.3% in the 3rd quarter. Albion Financial Group UT now owns 129,980 shares of the financial services provider’s stock worth $18,925,000 after acquiring an additional 356 shares in the last quarter. 62.45% of the stock is owned by institutional investors.
iShares Biotechnology ETF Stock Performance
NASDAQ IBB opened at $148.02 on Friday. The stock’s 50 day moving average is $144.83 and its 200 day moving average is $140.93. iShares Biotechnology ETF has a twelve month low of $113.56 and a twelve month high of $150.57.
iShares Biotechnology ETF Dividend Announcement
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Further Reading
- Five stocks we like better than iShares Biotechnology ETF
- What is the S&P 500 and How It is Distinct from Other Indexes
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- What is the S&P/TSX Index?
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Roth IRA Calculator: Calculate Your Potential Returns
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.